UiPath Inc (NYSE:PATH) shares are moving higher in extended trading Tuesday after it was announced the company will join the S&P Midcap 400. UiPath shares are climbing with conviction. What’s behind PATH gains? What To Know: After the market close on Tuesday,…
As traders enter the final trading week of the year, Wall Street is eagerly watching out for the Santa Claus Rally. Going by recent trends, in 2025, the rally seems less like a tech-only celebration and more like a spreading…
If you're Googling holiday trash pickup times this week, you're not alone, and the companies behind those green and blue trucks have had a solid year on Wall Street. • Waste Management stock is trading in a tight range. Where…
Crypto mining has long been defined by boom-and-bust cycles. But HIVE Digital Technologies Ltd (NASDAQ:HIVE) says its next phase isn't about timing Bitcoin (CRYPTO: BTC) — it's about building a business that can perform across cycles. Track HIVE stock here.…
The U.S. economy just delivered a blockbuster third quarter, but traders are already betting that the pace will start to cool sharply. SPY ETF is trading near record highs. Check live chart here. Prediction markets reacted quickly after the stronger-than-expected…
The approval of Novo Nordisk's (NYSE:NVO)oral Wegovy is bringing new interest to health care and pharmaceutical ETFs that provide access to the growing GLP-1 market without requiring investors to choose one specific company. • What should traders watch with XLV?…
As traders enter the final trading week of the year, one familiar question dominates Wall Street chatter: Will the Santa Claus Rally show up again? • Newmont stock is trading near recent highs. What should traders watch with NEM? History says…
Wall Street traded modestly higher Wednesday, with large-cap benchmarks attempting a fourth straight day of gains as investors looked ahead to a seasonally strong year-end stretch. By midday in New York, the S&P 500 was up 0.4% near 6,900, hovering…
Pfizer Inc. (NYSE:PFE) disclosed the death of a participant in a long-term open-label extension study of marstacimab in patients with hemophilia A or B. In October 2024, the FDA approved Pfizer’s Hympavzi (marstacimab-hncq) for routine prophylaxis to prevent or reduce…
On Friday, BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) agreed to acquire Amicus Therapeutics, Inc. (NASDAQ:FOLD) for a total equity value of about $4.8 billion. "Immediately upon close, this transaction is expected to accelerate BioMarin's revenue growth and strengthen our financial outlook, delivering…